[The Process of Generating EULAR Recommendations]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2010 May 22

PMID 20490512

Citations 1

Authors

M Dougados

Affiliations

Soon will be listed here.

Abstract

Because of the complexity in interpretating the results obtained in original studies and the huge amount of new information available each month, a single rheumatologist is not able to adequately perform an optimal systematic literature research in order to apply this new information in his/her daily practice. These are the main reasons which prompted EULAR (European League against Rheumatism) to publish recommendations mainly for the management of the main musculoskeletal conditions seen in daily practice. These recommendations are written according to a strict methodology combining evidence-based medicine and expert opinions. These recommendations, prepared at the international level, should permit a uniformization of the management of rheumatic patients across the different European countries. All the EULAR initiatives have been generated by joint efforts of epidemiologists, young scientific fellows, and practicing rheumatologists (e.g., experts). Such a process has improved the knowledge of both the fellows and the experts in the field of clinical epidemiology.

Citing Articles

[Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence].

Kohm M, Behrens F Z Rheumatol. 2015; 74(5):398-405.

PMID: 26085072 DOI: 10.1007/s00393-014-1530-9.

References

Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004; 64(5):669-81. PMC: 1755499. DOI: 10.1136/ard.2004.028886. View

Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R . European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2009; 69(7):1269-74. PMC: 2952401. DOI: 10.1136/ard.2009.117200. View

Dougados M, Betteridge N, Burmester G, Euller-Ziegler L, Guillemin F, Hirvonen J . EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004; 63(9):1172-6. PMC: 1755117. DOI: 10.1136/ard.2004.023697. View

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68(5):620-8. DOI: 10.1136/ard.2008.096677. View

Combe B, Landewe R, Lukas C, Bolosiu H, Breedveld F, Dougados M . EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 66(1):34-45. PMC: 1798412. DOI: 10.1136/ard.2005.044354. View

Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2007; 67(2):195-205. DOI: 10.1136/ard.2007.070367. View

Zhang W, Doherty M, Peat G, Bierma-Zeinstra M, Arden N, Bresnihan B . EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2009; 69(3):483-9. DOI: 10.1136/ard.2009.113100. View

Hoes J, Jacobs J, Boers M, Boumpas D, Buttgereit F, Caeyers N . EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007; 66(12):1560-7. PMC: 2095301. DOI: 10.1136/ard.2007.072157. View

Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L . European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2008; 68(5):629-34. DOI: 10.1136/ard.2008.095299. View

10.

Gordon C, Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R . EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2008; 68(4):470-6. DOI: 10.1136/ard.2007.083022. View

11.

Mukhtyar C, Guillevin L, Cid M, Dasgupta B, de Groot K, Gross W . EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2008; 68(3):310-7. DOI: 10.1136/ard.2008.088096. View

12.

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P . EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10):1312-24. PMC: 1798308. DOI: 10.1136/ard.2006.055269. View

13.

Carville S, Arendt-Nielsen L, Arendt-Nielsen S, Bliddal H, Blotman F, Branco J . EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2007; 67(4):536-41. DOI: 10.1136/ard.2007.071522. View

14.

Jordan K, Arden N, Doherty M, Bannwarth B, Bijlsma J, Dieppe P . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12):1145-55. PMC: 1754382. DOI: 10.1136/ard.2003.011742. View

15.

Distler J, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F . EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2008; 68(2):163-8. DOI: 10.1136/ard.2008.091918. View

16.

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A, Gul A . EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008; 67(12):1656-62. DOI: 10.1136/ard.2007.080432. View

17.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C . Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008; 67(10):1360-4. DOI: 10.1136/ard.2008.091454. View

18.

Ozen S, Ruperto N, Dillon M, Bagga A, Barron K, Davin J . EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2005; 65(7):936-41. PMC: 1798210. DOI: 10.1136/ard.2005.046300. View

19.

Zhang W, Doherty M, Leeb B, Alekseeva L, Arden N, Bijlsma J . EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 66(3):377-88. PMC: 1856004. DOI: 10.1136/ard.2006.062091. View

20.

Zhang W, Doherty M, Leeb B, Alekseeva L, Arden N, Bijlsma J . EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis. 2008; 68(1):8-17. DOI: 10.1136/ard.2007.084772. View